Last month, we discussed Aduhelm, Biogen’s recently-approved Alzheimer’s drug that received pushback from medical professionals who believe the FDA put the cart ahead of the horse. Now, according to a New York Times article, two major medical centers, Cleveland Clinic and Mount Sinai, have decided not to administer the drug to patients.
Major Medical Centers Are Nixing Aduhelm
The controversial new Alzheimer’s drug may be FDA-approved, but there’s no shortage of critics.
Jul 21, 2021
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
